196 related articles for article (PubMed ID: 34139789)
21. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
22. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
24. How to manage the infectious risk under anti-TNF in inflammatory bowel disease.
Culver EL; Travis SP
Curr Drug Targets; 2010 Feb; 11(2):198-218. PubMed ID: 20210768
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory bowel disease: perioperative pharmacological considerations.
Kumar A; Auron M; Aneja A; Mohr F; Jain A; Shen B
Mayo Clin Proc; 2011 Aug; 86(8):748-57. PubMed ID: 21803957
[TBL] [Abstract][Full Text] [Related]
26. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
27. Which patients with inflammatory bowel disease should receive combination therapy?
Cross RK
Expert Rev Gastroenterol Hepatol; 2015 Jun; 9(6):715-7. PubMed ID: 25912620
[TBL] [Abstract][Full Text] [Related]
28. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
[TBL] [Abstract][Full Text] [Related]
29. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
30. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.
Lew D; Yoon SM; Yan X; Robbins L; Haritunians T; Liu Z; Li D; McGovern DP
World J Gastroenterol; 2017 Oct; 23(40):7265-7273. PubMed ID: 29142473
[TBL] [Abstract][Full Text] [Related]
31. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
32. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1.
Bremmer M; Deng A; Gaspari AA
Dermatitis; 2009; 20(4):182-92. PubMed ID: 19804694
[TBL] [Abstract][Full Text] [Related]
33. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.
Degasperi E; Caprioli F; El Sherif O; Back D; Colombo M; Aghemo A
Expert Rev Gastroenterol Hepatol; 2016 Dec; 10(12):1373-1383. PubMed ID: 27718758
[TBL] [Abstract][Full Text] [Related]
34. Risk of non-melanoma skin cancer with thiopurine use in inflammatory bowel disease.
Subramaniam K; Pavli P
J Gastroenterol Hepatol; 2012 Feb; 27(2):193-4. PubMed ID: 22260282
[No Abstract] [Full Text] [Related]
35. Toxicity profile of thiopurines in inflammatory bowel disease: a retrospective cohort analysis.
Labidi A; Hafi M; Ben Mustapha N; Serghini M; Fekih M; Boubaker J
Tunis Med; 2020 May; 98(5):404-412. PubMed ID: 32548844
[TBL] [Abstract][Full Text] [Related]
36. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
37. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory bowel disease: current therapeutic options.
Domènech E
Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
40. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
